Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 232 for “"HER-2"”.

  1. HER-2/neu-targeted immunoprevention of breast cancer

    … in the use of traditional breast cancer therapies have improved the overall survival of women with early stage disease. Remarkable advances in research have created a unique opportunity for developing active vaccination strategies that engage the body’s own immune system in the fight …

    sask Repository record for HER-2/neu-targeted immunoprevention of breast cancer (opens in a new tab)

  2. Πειραματικά μοντέλα ανοσοθεραπείας HER-2/neu θετικών όγκων

    Overexpression of the HER-2/neu oncogene by a significant number of human carcinomas has been associated with more aggressive disease. Despite its high oncogenic potential, HER2/neu oncoprotein has been considered as a promising target for cancer therapeutics as it has been proven to be immunogenic …

    greece Repository record for Πειραματικά μοντέλα ανοσοθεραπείας HER-2/neu θετικών όγκων (opens in a new tab)

  3. HER-2/neu, Topoisomerase-II-α, Östrogen- und Progesteronrezeptor

    … der Frau dar. Die Wahl der geeigneten Therapie wird für das metastasierte Mammakarzinom anhand des pathologisch untersuchten Gewebes des Primärtumors getroffen. Die Untersuchung der biologischen Marker von Fernund lokoregionären Lymphknotenmetastasen wird routinemäßig nicht durchgeführt. …

    lmu-germany Repository record for HER-2/neu, Topoisomerase-II-α, Östrogen- und Progesteronrezeptor (opens in a new tab)

  4. Ανοσοθεραπεία στον HER-2 θετικό καρκίνο του μαστού: Συστηματική ανασκόπηση

    … είναι ο πιο συχνός καρκίνος στις γυναίκες. Ο HER-2 θετικός καρκίνος του μαστού είναι ένας επιθετικός υποτύπος. Παρά το γεγονός ότι οι αντι-HER2 θεραπείες έχουν βελτιώσει τη συνολική επιβίωση των ασθενών με μεταστατικό καρκίνο του μαστού με μέσο όρο άνω των 5 ετών, υπάρχει ανάγκη για ακόμα …

    athens Repository record for Ανοσοθεραπεία στον HER-2 θετικό καρκίνο του μαστού: Συστηματική ανασκόπηση (opens in a new tab)

  5. HER-2/neu Genamplifikation und Rezeptorüberexpression in verschiedenen Tumoren des Ovars

    Die vorgelegte Arbeit beschäftigt sich mit der Her-2/neu Genamplifikation und der Her-2/neu Rezeptorüberexpression in verschiedenen Tumoren des Ovars. Untersucht wurden diese Veränderungen mit der Fluoreszenz-in situ-Hybridisierung und der Immunhistochemie. Die Ergebnisse bei den Ovarialkarzinomen …

    lmu-germany Repository record for HER-2/neu Genamplifikation und Rezeptorüberexpression in verschiedenen Tumoren des Ovars (opens in a new tab)

  6. Proteomics analysis of Her-2/neu-linked protein profiles in tumor microenvironment

    … proteomics had been employed to analyze the HER-2/neu-linked protein profiles in breast tumor microenvironment. Proteome profiles of the HER-2/neu-positive and -negative breast tumors were generated with two-dimensional gel electrophoresis. Combinations of different pH ranges of IPG …

    nus Repository record for Proteomics analysis of Her-2/neu-linked protein profiles in tumor microenvironment (opens in a new tab) Download file for Proteomics analysis of Her-2/neu-linked protein profiles in tumor microenvironment (opens in a new tab)

  7. Novel targeted agents in Her-2 positive and triple negative breast cancer

    The development of Her-2 targeted therapies has improved the prognosis for patients with Her-2 positive breast cancer. However, not all Her-2 positive tumours respond to treatment with Her-2 antagonists. Triple negative cancers are resistant to hormone and Her-2 targeted therapies. This project …

    dcu Download PDF for Novel targeted agents in Her-2 positive and triple negative breast cancer (opens in a new tab)

  8. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

    … promising effectors for tumor adoptive immunotherapy, particularly when considering the targeting of MHC class I low or negative tumors. Yet, many tumor cells are resistant to NK killing, which is mainly the case for non-hematopoietic tumors such as carcinomas or melanoma, even when these cells …

    fu-berlin Repository record for Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas (opens in a new tab)

  9. Bedeutung des Her-2/neu beim Ovarialkarzinom - Korrelation und Vergleich mit klinischen Prognosefaktoren

    … wird eine immunhistochemische Bestimmung des Her-2/neu - Status vorgenommen, der beim Mamma-Karzinom als unabhängiger Prognosefaktor bekannt ist und mit einer schlechteren Prognose einhergeht. Zusammenfassend ließ sich in dieser Arbeit keine Überexpression des Her-2/neu am Ovar feststellen, …

    wurz-thes Repository record for Bedeutung des Her-2/neu beim Ovarialkarzinom - Korrelation und Vergleich mit klinischen Prognosefaktoren (opens in a new tab)

  10. Evidencia sobre la expresión de Her-2 en la enfermedad de Paget Extramamaria

    … potential to produce metastasis and even death. HER2 is a biomarker that is currently under study due to its clinical implications in the diagnosis, evolution and prognosis of the disease. The present study proposes to identify the evidence related to the behavior of this biomarker in …

    rosario Repository record for Evidencia sobre la expresión de Her-2 en la enfermedad de Paget Extramamaria (opens in a new tab)

  11. Expressão imuno-histoquímica das proteínas VEGF e HER-2 em biópsias de osteossarcoma

    … encontrado geralmente em jovens. VEGF e HER-2 têm sido utilizados em diversos tipos de tumores como possíveis marcadores de imuno-histoquímica relacionados ao prognóstico; no entanto, estudos realizados em osteossarcomas ainda apresentam resultados contraditórios. Objetivos: Identificar a …

    brazil-ufrgs Repository record for Expressão imuno-histoquímica das proteínas VEGF e HER-2 em biópsias de osteossarcoma (opens in a new tab)

  12. Expressão de HER-2/neu e p53 em adenocarcinoma de esôfago e cárdia

    … de estudos da patogênese destes tumores. HER-2/neu é um oncogene expresso in diversas neoplasias e relacionado à pior prognóstico. P53 é igualmente importante estando mutado em 50%-70% das neoplasias sólidas com implicações clínicas para muitos tumores. Este trabalho determina a frequência …

    brazil-ufrgs Repository record for Expressão de HER-2/neu e p53 em adenocarcinoma de esôfago e cárdia (opens in a new tab)

  13. The role of EGFR, HER 2-4, heregulin and downstream signalling in prostate adenocarcinoma

    … Currently evidence regarding influence of the HER tyrosine kinase family - EGFR, HER2, HER3 and HER4 - during disease progression in prostate adenocarcinoma is conflicting – both poor prognosis and no influence on outcome are reported. A small cohort pilot study of paired hormone sensitive …

    glasgow Download PDF for The role of EGFR, HER 2-4, heregulin and downstream signalling in prostate adenocarcinoma (opens in a new tab)

  14. Topoisomerase ll-a e Her-2 em tumores malignos de mama e de ovário

    Introdução. O receptor epidérmico humano 2 (Her-2) e a topoisomerase-IIα (T2A) são dois marcadores biológicos importantes, ambos tendo um valor prognóstico e preditivo potencial em pacientes com tumores sólidos. A amplificação dos genes Her- 2 e T2A são eventos independentes, embora o último seja …

    brazil-ufrgs Repository record for Topoisomerase ll-a e Her-2 em tumores malignos de mama e de ovário (opens in a new tab)

  15. Ανάπτυξη και αξιολόγηση συστημάτων χορήγησης πεπτιδικών αντιγόνων HER-2/neu συνδεδεμένων με PLA μικροσφαίρες

    Despite the progress of classic therapeutic strategies developed concerning cancer the greatest number of patients deteriorates and eventually dies. The need to confront this disease in an alternative way has led to the development of new immunotherapeutic methods. The identification of …

    greece Repository record for Ανάπτυξη και αξιολόγηση συστημάτων χορήγησης πεπτιδικών αντιγόνων HER-2/neu συνδεδεμένων με PLA μικροσφαίρες (opens in a new tab)

Page 1 of 12